CSIMarket
 
Boston Scientific Corporation  (NYSE: BSX)
Other Ticker:  
 
 
Price: $105.2500 $0.23 0.219%
Day's High: $105.92 Week Perf: 2.12 %
Day's Low: $ 104.29 30 Day Perf: 14.41 %
Volume (M): 5,538 52 Wk High: $ 107.17
Volume (M$): $ 582,906 52 Wk Avg: $80.31
Open: $104.75 52 Wk Low: $64.55



 Market Capitalization (Millions $) 156,549
 Shares Outstanding (Millions) 1,487
 Employees 48,000
 Revenues (TTM) (Millions $) 15,911
 Net Income (TTM) (Millions $) 1,787
 Cash Flow (TTM) (Millions $) 1,517
 Capital Exp. (TTM) (Millions $) 780

Boston Scientific Corporation
Company Profile: Boston Scientific Corporation

Overview:
Boston Scientific Corporation is a global leader in the development, manufacturing, and marketing of medical devices. Founded in 1979, the company focuses on advancing the practice of less-invasive medicine through a comprehensive range of innovative products, technologies, and services within various interventional medical specialties, including but not limited to interventional cardiology, peripheral interventions, neurovascular intervention, electrophysiology, vascular surgery, endoscopy, oncology, urology, and gynecology.

Product Offerings:
Boston Scientific's product portfolio includes devices that are typically inserted into the human body through natural openings or small incisions, allowing for minimally invasive diagnosis and treatment of a wide array of medical conditions. These products significantly enhance patient outcomes by providing alternatives to traditional surgery, improving overall quality of life for patients.

The company is particularly recognized for its leadership in the interventional cardiology market, where its advanced coronary stent offerings are vital in treating coronary artery disease. Boston Scientific is dedicated to improving coronary stent performance by researching and developing innovative solutions to address challenges like in-stent restenosis.

Business Structures:
Boston Scientific operates through two primary business groups:
1. Cardiovascular: This group develops products and technologies utilized in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, and neurovascular procedures.
2. Endosurgery: This group focuses on oncology, endoscopy, urology, and gynecology.

The company launched a master branding initiative to unify its brand identity, transitioning from a collection of divisional brands to a single, cohesive entity. This initiative aims to enhance recognition and brand equity for Boston Scientific as a whole.

Market Presence:
The company sells its products to over 10,000 hospitals, clinics, outpatient facilities, and medical offices globally, mitigating dependency on any single institution. Additionally, Boston Scientific distributes select products for third-party manufacturers, including introducer sheaths, guidewires, and acellular tissue used in urology and gynecology.

International Operations:
Boston Scientific is structured into three geographic segments: Europe, Japan, and Inter-Continental, enabling it to cater to regional needs while maintaining strong global outreach.

Competition:
Boston Scientific faces intense competition across its product lines from various companies, many of which possess significant financial and marketing resources. Key competitors include Abbott Laboratories, Cook, Inc. Guidant Corporation (and its subsidiary Advanced Cardiovascular Systems, Inc.), Johnson & Johnson (through its subsidiary Cordis Corporation), and Medtronic, Inc. (including its subsidiary Medtronic AVE, Inc.). The competitive landscape also includes numerous companies specializing in specific markets or offering limited product lines.

Conclusion:
As a pioneer in the medical device industry, Boston Scientific Corporation continues to push the boundaries of innovation in less-invasive medical technology, aiming to improve patient outcomes and provide healthcare professionals with advanced therapeutic options.


   Company Address: 300 Boston Scientific Way Marlborough 1752 MA
   Company Phone Number: 683-4000   Stock Exchange / Ticker: NYSE BSX


Customers recorded net loss Customers recorded net loss



• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -3.22%    
BDX   -7.17%    
ISRG        0.77% 
MDT   -0.57%    
SYK        0.07% 
ZBH   -6.68%    
• View Complete Report
   



Boston Scientific Corporation

Strategic Partnerships and Strong Financial Performance Drive Boston Scientific's Success in Q1 2024



Boston Scientific Corporation, a leading player in the global medical technology sector, has recently reported its financial results for the first quarter of 2024. The company showcased impressive performance, witnessing substantial increases in profitability, revenue, and net earnings. Additionally, Boston Scientific has expanded its strategic partnership with Scivita Medical Technology Co., Ltd., emphasizing the growing demand for advanced medical devices globally. The company's shares have also experienced positive gains, further highlighting its strength in the market.
Financial Highlights:
1. Profitability: Boston Scientific witnessed a jump in profitability, with earnings per share increasing by 57.14% to $0.33 in Q1 2024, compared to the prior year period's $0.30 per share.
2. Revenue Boost: The company's revenue surged by 13.809% to reach $3.86 billion in Q1 2024, outperforming its industry peers, who reported an average business improvement of 5.79% during the same period.
3. Favorable Comparative Growth: Compared to the previous reporting period, the company's income improved by 8.93%, and revenue surged by 3.544%.
4. Net Earnings: Boston Scientific's bottom-line grew significantly, with net earnings reaching $493 million in Q1 2024, a year-on-year increase of 57.01% from the $314 million reported in the same period the previous year.
5. Profit Margin: Boston Scientific highlighted its improving profit margins, with the net margin rising to 12.78% and the operating margin edging up to 17.5% in Q1 2024.

Contract

Scivita Medical and Boston Scientific Foster Strong Collaboration Amidst Growing Healthcare Industry

Published Tue, Mar 26 2024 1:30 AM UTC

In a recent move, Scivita Medical Technology Co., Ltd. (Scivita Medical) and Boston Scientific Corporation (NYSE: BSX) have further solidified their strategic partnership in the global medical technology sector. The expanded collaboration between the two leading healthcare companies reflects the increasing demand for innovative solutions and advanced medical devices worldwid...

Contract

Axonics Stockholders Approve Merger Agreement with Boston Scientific as Company Outperforms Competitors

Published Fri, Mar 22 2024 8:01 PM UTC

In a significant development for the medical technology industry, Axonics, Inc. announced that its stockholders have voted in favor of adopting the merger agreement with Boston Scientific Corporation. This decision marks a crucial step towards solidifying the partnership and signifies the market s confidence in the potential benefits that lie ahead. Moreover, amidst a challe...

Stock Offering

Boston Scientific's $2 Billion Senior Notes Offering: Empowering Innovation in Healthcare

Published Fri, Feb 23 2024 2:27 AM UTC



Boston Scientific Corporation (NYSE: BSX), a leading medical technology company, has announced the successful pricing of $2 billion in senior notes by its wholly owned finance subsidiary, American Medical Systems Europe B.V. This significant offering demonstrates the company s robust financial position and signals its continued commitment to innovation and growth i...

Boston Scientific Corporation

Boston Scientific Corporation Makes Giant Leap in Urology with $3.7 Billion Acquisition

Axonics, Inc.'s definitive agreement to be acquired by Boston Scientific Corporation for the impressive sum of $3.7 billion marks a significant milestone in the field of urology medical devices. This game-changing deal is set to reshape the landscape of sacral neuromodulation therapy for bladder and bowel dysfunction, solidifying Boston Scientific's position in the market and expanding its product portfolio. With a strong commitment to innovation and improving patient outcomes, Boston Scientific's acquisition of Axonics is poised to drive advancements in urology medical devices and ultimately benefit patients worldwide.
Boston Scientific Corporation, known for its dedication to research and development, operates with a business model focused on designing, developing, and manufacturing a wide range of medical devices across various medical specialties. With a global presence and robust sales and distribution networks, the company is able to effectively deliver its products to healthcare professionals and hospitals around the world. Boston Scientific's emphasis on introducing cutting-edge technologies and solutions to the market has positioned it as a leader in the medical device industry.







Boston Scientific's Segments
MedSurg    35.14 % of total Revenue
Cardiovascular    64.88 % of total Revenue
BSX Reportable Segments    99.29 % of total Revenue
United States    61.61 % of total Revenue
United States MedSurg    23.92 % of total Revenue
United States Cardiovascular    37.68 % of total Revenue
International    38.39 % of total Revenue
International MedSurg    11.21 % of total Revenue
International Cardiovascular    27.2 % of total Revenue
Endoscopy    16.11 % of total Revenue
Endoscopy United States    9.91 % of total Revenue
Endoscopy International    6.2 % of total Revenue
Urology    12.64 % of total Revenue
Urology United States    9 % of total Revenue
Urology International    3.64 % of total Revenue
Neuromodulation    6.37 % of total Revenue
Neuromodulation United States    5.01 % of total Revenue
Neuromodulation International    1.35 % of total Revenue
Interventional Cardiology Therapies    15.7 % of total Revenue
Interventional Cardiology Therapies United States    5.04 % of total Revenue
Interventional Cardiology Therapies International    10.67 % of total Revenue
Watchman    9.03 % of total Revenue
Watchman United States    8.13 % of total Revenue
Watchman International    0.9 % of total Revenue
Cardiac Rhythm Management    13.33 % of total Revenue
Cardiac Rhythm Management United States    8.29 % of total Revenue
Cardiac Rhythm Management International    5.06 % of total Revenue
Electrophysiology    12.52 % of total Revenue
Electrophysiology United States    8.7 % of total Revenue
Electrophysiology International    3.8 % of total Revenue
Cardiology    50.58 % of total Revenue
Cardiology United States    30.15 % of total Revenue
Cardiology International    20.41 % of total Revenue
Peripheral Interventions    14.3 % of total Revenue
Peripheral Interventions United States    7.51 % of total Revenue
Peripheral Interventions International    6.77 % of total Revenue
United States BSX Reportable Segments    61.61 % of total Revenue
EMEA BSX Reportable Segments    18.37 % of total Revenue
APAC BSX Reportable Segments    16.25 % of total Revenue
Latin America and Canada BSX Reportable Segments    3.78 % of total Revenue
Emerging Markets    16.25 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com